Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures. It has collaboration agreements with the University of Glasgow for prognostic and predictive profiling of COVID-19 patients in the GETAFIX. Oxford BioDynamics Plc was founded in 2007 and is headquartered in Oxford, the United Kingdom.